Entegrion continually seeks collaborations with premier organizations closely aligned with our mission to advance the safety and availability of human-derived therapeutics. We welcome discussions on alliances, licensing and joint ventures.

Leading Research Institutions

We are privileged to work with an impressive group of medical research facilities and look forward to growing our base of research partners.

  • University of North Carolina. Our initial partnership with UNC was a natural occurrence due to the strong relationship that Entegrion’s Dr. Arthur Bode has with his alma mater. Over the years, we expanded our relationships within UNC and to other institutions.

Among the institutions that have contributed to our product advancement through in vitro and in vivo studies and product evaluation are:

Corporate Partners

Kedrion has formalized agreements with Entegrion in support of our Resusix™ project. Kedrion’s solvent detergent treated plasma serves as the precursor to Resusix™, and the company’s technical competencies helped Resusix™ advance to IND within 3 years of product concept.

Beeken Biomedical is a diversified wound care company located in Pennsylvania that licensed Entegrion’s Stasilon®, a dual fiber, minimally adherent hemostatic textile that supports rapid hemostasis of bleeding surfaces. Beeken now exclusively markets and distributes Stasilon®.

Government Partners

Office of Naval Research (ONR) provided the initial funding for Resusix™ from concept through phase 1 trials and provided the initial funding for our MRF.

Defense Medical Research and Development Program (DMRDP) provided additional funding for Resusix™.

Congressionally Directed Medical Research Program (CDMRP)  through the Secretary of Defense provided the final funding for Resusix™ as well as funding for our PCM.

Entegrion complies with applicable Federal Conflict of Interest rules.

Industry Associations

our technologies are responsive to our military’s strong interest in saving lives wherever our people serve—by breaking the cold chain dependency of blood component therapy.